Key result
Plasma N-BNP levels were significantly higher in children with congestive heart failure (mean 846 fmol/mL) compared to controls (mean 311 fmol/mL) and correlated with clinical severity.
Why the study?
Do plasma N-BNP levels correlate with ejection fraction and clinical symptoms in children with congestive heart failure?
Observational (n=164)
Do plasma N-BNP levels correlate with ejection fraction and clinical symptoms in children with congestive heart failure?
Plasma N-BNP levels are significantly elevated in children with congestive heart failure and correlate with both clinical symptom severity and impaired ejection fraction.
OBJECTIVE: To determine plasma levels of N-terminal pro-brain natriuretic peptide (N-BNP) in control children to establish a normal age-dependent range from the neonatal period to adulthood. In addition, plasma concentrations of N-BNP were measured in children with congestive heart failure (CHF) and correlated with ejection fraction and clinical symptoms of heart failure. METHODS: For establishing a normal age-dependent range of plasma N-BNP, venous blood samples were taken in 133 control patients from the neonatal period to adulthood (10 days-32 years) and in 31 children with CHF. Plasma N-BNP levels were determined by an enzyme immunoassay. In children (1 month-14 years) with CHF, plasma N-BNP levels were correlated to ejection fraction measured by echocardiography and clinical symptoms of heart failure using the Ross Score. RESULTS: N-BNP levels in control children, adolescents, and adults did not show a significant age-related difference. In control children, the normal range was established between 150 (10th percentile) and 430 fmol/mL (90th percentile). Mean plasma N-BNP in control children was 311 fmol/mL (range: 74-654 fmol/mL). In 31 children with CHF, the plasma N-BNP levels were significantly higher (mean: 846; range: 219-2718) than in control children. N-BNP levels showed a negative correlation with the ejection fraction (r = -0.53) and a positive correlation with the clinical heart failure score (r = 0.74). CONCLUSIONS: Plasma N-BNP levels reflect the severity of symptoms of heart failure and the impairment of cardiac function in children with CHF. In the future, determination of plasma N-BNP levels may be used as a helpful adjunct to monitor the effect of various treatments for CHF in children.
No takes yet. Share an insight, caveat, or question.
Mir et al. (2002) conducted an observational in Congestive heart failure (n=164). Plasma N-BNP measurement vs. Healthy controls was evaluated on Plasma N-BNP levels. Plasma N-BNP levels were significantly higher in children with congestive heart failure (mean 846 fmol/mL) compared to controls (mean 311 fmol/mL) and correlated with clinical severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: